Stress Urinary Incontinence

Summary

Introduction

Stress urinary incontinence (SUI) is the most common type of urinary incontinence in women. Up until recently there were no globally developed or widely approved pharmacological treatments for this disorder leaving women with few treatment optionsnon-invasive (e.g. pelvic floor exercises) or invasive (i.e. surgery) non-pharmacological therapy.

Scope

• Quantitative treatment data from 419 physicians based in US, Japan, France, Germany, Italy, Spain and the UK; supported by key opinion leader comments
• Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line pharmacological treatments for SUI
• Influences on treatment choice and perception of current drug therapies including duloxetine
• Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline

Highlights

• Despite the high prevalence of SUI among women, a number of factors including embarrassment and poor awareness amongst women act as a barrier to sufferers seeking help for their condition. There is a need for better education and treatment options to improve diagnosis and treatment rates.
• Without the widespread availability of an efficacious drug for SUI, many physicians have become reliant on non-pharmacological techniques. Patients and primary care physicians, with little experience of surgery, are less likely to be confident with this treatment option and it is here that pharmacological treatments could gain more support.
• The approval of Yentreve (duloxetine) for SUI in the EU has provided another treatment option. However, uptake has not been as rapid as Lilly would have hoped and although this may have been influenced by satisfaction with surgical treatment, to date the available clinical data and experience in clinical practice, has not always been positive.

Reasons to Purchase

• Forecast product sales by understanding key aspects of SUI epidemiology, diagnosis and treatment
• Gain a better understanding of the challenges facing current and future players in the SUI market
• Identify physicians key concerns in SUI including unmet needs and the attributes that physicians believe are desirable for future treatments

Contents

• This product has been designed for delivery in a slide pack format (PowerPoint).
• Please select the slide pack option from the download menu at the side of the page
• Introduction
• Scope of this report
• Research and analysis highlights
• Key reasons to read this report
• Appendix A
  • Research methodology
  • Physician Sample breakdown
  • Urinary Incontinence and Overactive Bladder Insight Study - Physician Questionnaire
  • Section One Overview of Urinary Incontinence and overactive Bladder
  • Epidemiology
  • Presentation
  • Diagnosis
  • Referral pattern
  • Section Two Stress Urinary Incontinence
  • Diagnosis and treatment of SUI
  • Non-pharmacological treatment
  • Pharmacological treatment for SUI
  • Section Three Overactive Bladder With Urge Symptoms and/or Incontinence
  • Diagnosis and treatment of UUI
  • Pharmacological treatment for UUI
  • Diagnosis and treatment of 'dry OAB'
  • Pharmacological treatment for dry OAB
  • Section Four Mixed Stress/Urge Urinary Incontinence
  • Diagnosis and treatment of mixed SUI/UUI
  • Non-pharmacological treatment
  • Pharmacological treatment for mixed SUI/UUI
  • Section Five Interstitial Cystitis
  • Diagnosis and treatment of IC
  • Pharmacological treatment for IC
  • Section Six Drug Profiles
  • Section A: Drug influences on physicians' choice
  • Section B: The general treatment of urinary incontinence and overactive bladder
  • Contributing experts
  • US
  • Japan
  • Europe
• Appendix B
  • About Datamonitor
  • About Datamonitor Healthcare
  • About the CNS analysis team
  • Disclaimer